The After-Hours EDR Gap Biotech Leaders Do Not Want to Talk About
The most dangerous security gap in a biotech company is not always a missing tool.
Sometimes it is a legitimate alert that arrives when nobody is ready to act.
That is the after-hours problem. And for biotech companies under $100M, it is one of the most under-discussed risks in the security program.
Most leadership teams assume their endpoint detection and response platform is protecting them because it is always running. Technically, that may be true. The agent is installed. The dashboard is active. Alerts are generated. Some threats may even be blocked automatically.
But protection is not the same as monitoring. Monitoring is not the same as investigation. Investigation is not the same as containment. And containment is not the same as a coordinated incident response.
That chain matters.
A biotech company can spend a small fortune on EDR and still have a serious exposure window every night, every weekend, and every holiday. Not because the tool is incapable. Because the operating model behind the tool is thin.
This is where leadership needs to be honest.
If a high-severity EDR alert fires at 2:13 a.m., what actually happens?
Not what the policy says. Not what the vendor brochure says. What happens in real life?
Does a trained analyst review it immediately?
Does someone validate whether it is malicious or a false positive?
Does someone check whether the user’s account is also showing suspicious login behavior?
Does someone determine whether the endpoint has access to sensitive research, regulated records, or clinical trial data?
Does someone have authority to isolate the machine?
Does someone escalate to internal IT, security leadership, legal, or executives based on the data involved?
Or does the alert wait?
That waiting period is where risk grows.
The biotech sector does not have the luxury of treating cyber response as a normal business-hours function. Research work is distributed. Cloud systems are always online. Employees travel. Vendors connect remotely. Data moves across collaboration platforms, lab systems, storage environments, and SaaS applications. Attackers do not need your whole company to be offline to cause damage. They need one foothold, one exposed account, one unmanaged device, or one delayed containment decision.
Verizon’s 2026 DBIR shows why this matters. The report says 48% of breaches now involve ransomware and 31% start with software vulnerabilities. That should make biotech leaders uncomfortable because vulnerability exploitation and ransomware do not respect staffing calendars.
IBM’s 2025 Cost of a Data Breach report also reinforces the business value of faster identification and containment. IBM reported a global average breach cost of $4.4 million and attributed the year-over-year decrease partly to faster identification and containment.
That is the point. Speed is not a technical preference. Speed is a financial and operational control.
In biotech, the cost of slow response can show up in several ways.
It can show up as intellectual property exposure when a compromised account accesses research folders or proprietary data.
It can show up as clinical disruption when systems needed for trial coordination, data review, documentation, or vendor collaboration are locked, investigated, or taken offline.
It can show up as compliance exposure when leadership cannot quickly answer what happened, what data was involved, who accessed it, when it was contained, and what evidence supports those conclusions.
It can show up as investor concern when the company cannot explain whether the event was limited, material, contained, or still under investigation.
It can show up as operational downtime when IT is forced into emergency mode because a security event was not handled early.
This is why EDR without after-hours response creates a false sense of maturity.
The company looks protected from the outside. Internally, the model depends on a small IT team seeing the right alert, interpreting it correctly, and responding quickly while also supporting every other operational demand.
That is not a security strategy. That is hope with a dashboard.
This does not mean internal IT is failing.
In most biotech companies, internal IT is being asked to do too much with too little. They are supporting users, onboarding staff, managing endpoints, helping scientists access systems, maintaining cloud resources, dealing with vendors, answering executive requests, handling compliance evidence, and keeping the business moving. Then leadership adds security operations on top and expects the same team to monitor threats 24×7.
That model breaks quietly before it breaks publicly.
At first, the cracks look harmless. Alerts are reviewed later. Low-confidence detections are ignored. Investigation notes are thin. After-hours escalation is informal. Containment decisions depend on who happens to be available. False positives train the team to move slower. No one wants to isolate a researcher’s device during a critical workflow. Nobody wants to be the person who disrupts the business.
Attackers benefit from that hesitation.
A mature security operation does not eliminate every incident. That is not realistic. What it does is reduce ambiguity when an incident begins.
Managed security services should be viewed through that lens. Not as outsourcing. Not as a shortcut. Not as an admission that internal IT cannot handle security. A serious MSSP is a way to install a response operating model around the company’s risk profile.
For biotech, that matters because the risk profile changes faster than the headcount.
A company can move from early-stage research to clinical activity, partnerships, fundraising, regulatory scrutiny, and commercialization pressure before the security team has time to mature. The attack surface expands. The value of the data increases. The number of vendors grows. The cost of disruption rises.
But the IT team may still be two, three, or five people.
That mismatch is the real problem.
A strong managed security model gives the company experienced threat analysts, defined escalation paths, after-hours monitoring, documented response procedures, containment support, and response times leadership can measure. More importantly, it gives internal IT a partner that lives in security operations every day.
That experience matters.
When a suspicious endpoint event occurs, an experienced analyst does not just ask, “Did the EDR block it?” The analyst asks: What process launched? What user was involved? Was privilege escalation attempted? Did the endpoint communicate externally? Are there related alerts on other systems? Was PowerShell abused? Did the user authenticate from unusual locations? Did any sensitive directories or cloud repositories get touched? Does this look isolated or coordinated?
That kind of investigation cannot be replaced by a dashboard.
It requires process, repetition, and judgment.
Directors of IT and CISOs should use practical decision criteria when evaluating whether their current model is robust enough.
First, measure alert review speed. Can you prove how quickly high-severity EDR alerts are reviewed during nights and weekends?
Second, measure investigation depth. Are alerts being enriched with identity, cloud, email, firewall, VPN, and network context?
Third, measure containment authority. Who can isolate an endpoint, disable an account, block traffic, or escalate to leadership?
Fourth, measure documentation quality. Can your team produce a clear incident record that explains what happened, what was affected, what actions were taken, and what remains unknown?
Fifth, measure business alignment. Are response rules different for research systems, executive devices, finance users, clinical data repositories, and general endpoints?
Sixth, measure provider accountability. If you use an MSSP, are they responsible for real triage and response guidance, or are they simply forwarding alerts?
That last question is critical.
Not every managed security provider is equal. Some sell monitoring but avoid response. Some send alerts but do not investigate deeply. Some hide behind portals. Some escalate too slowly. Some cannot explain their process without drowning the client in technical language.
Biotech leaders should demand clarity.
Ask the provider what happens during the first 15 minutes of a high-severity EDR alert. Ask what evidence they collect. Ask how they decide whether to isolate a machine. Ask when they involve internal IT. Ask how they treat alerts involving research data or regulated information. Ask whether response times are guaranteed or merely “best effort.” Ask for examples of incidents they have handled where early containment changed the outcome.
The answers will tell you whether you are buying a security operation or another notification layer.
Real incidents show why this matters. Inotiv, a contract research organization, disclosed that a threat actor gained unauthorized access to certain systems during an August 2025 incident and may have acquired data. The company reported taking containment steps, engaging external cybersecurity specialists, and notifying regulators and law enforcement.
Novo Nordisk also illustrates the value attackers place on pharmaceutical data. Reuters reported that a cyber extortion group claimed to have stolen more than a terabyte of data from the company, allegedly including proprietary drug information, trial data, source code, and internal AI model information; Reuters noted it could not immediately verify the authenticity of the posted data.
These examples are not being raised to scare leadership. They are raised because they expose the real issue: cyber incidents in this sector quickly become business, legal, regulatory, and trust events.
That is why “we have EDR” is not enough.
The better question is: “Can we respond when it matters?”
If your company cannot answer that with evidence, then the security program is not as mature as it looks.
Managed security services become strategic when they close the gap between detection and action. They give biotech companies a way to operate with security experience they may not be ready to hire internally. They provide coverage during the hours when lean teams are most exposed. They create response discipline before the incident forces leadership to build it under pressure.
That is not a shortcut.
It is a more honest operating model.
Biotech leadership should not wait until an after-hours alert becomes a board-level conversation. The time to test the model is before the incident, not during it.
Because the real question is not whether your EDR can see the threat.
The real question is whether your company is prepared to act before the threat becomes a business event.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
